Tenaya TherapeuticsTNYA
TNYA
About: Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
Employees: 140
0
Funds holding %
of 6,794 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
2,000% more call options, than puts
Call options by funds: $21K | Put options by funds: $1K
89% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 19
0.39% more ownership
Funds ownership: 72.66% [Q2] → 73.05% (+0.39%) [Q3]
0% more funds holding
Funds holding: 95 [Q2] → 95 (+0) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 17
37% less capital invested
Capital invested by funds: $177M [Q2] → $111M (-$65.7M) [Q3]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$16
347%
upside
Avg. target
$17.60
392%
upside
High target
$18
403%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 29% 1-year accuracy 81 / 283 met price target | 403%upside $18 | Buy Reiterated | 26 Nov 2024 |
HC Wainwright & Co. Joseph Pantginis 29% 1-year accuracy 81 / 283 met price target | 403%upside $18 | Buy Reiterated | 25 Nov 2024 |
Chardan Capital Geulah Livshits 32% 1-year accuracy 14 / 44 met price target | 403%upside $18 | Buy Maintained | 7 Nov 2024 |
Canaccord Genuity Whitney Ijem 40% 1-year accuracy 12 / 30 met price target | 347%upside $16 | Buy Maintained | 18 Oct 2024 |
HC Wainwright & Co. Joseph Pantginis 29% 1-year accuracy 81 / 283 met price target | 403%upside $18 | Buy Reiterated | 18 Oct 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in the MyPEAK TM -1 Phase 1b/2 Trial of TN-201 Gene Therapy
Neutral
GlobeNewsWire
1 month ago
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling
Neutral
GlobeNewsWire
3 months ago
Tenaya Therapeutics to Participate in Upcoming Investment Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's chief Executive Officer, will participate in several upcoming investment conferences. Details are as follows:
Positive
24/7 Wall Street
4 months ago
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street
Penny stocks represent an interesting investment opportunity.
Neutral
GlobeNewsWire
5 months ago
Tenaya Therapeutics Announces Research Leadership Updates
Kathy Ivey, Ph.D., Promoted to Senior Vice President, Research and Timothy Hoey, Ph.D., Transitions to Advisory Role
Neutral
GlobeNewsWire
5 months ago
Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will participate in the TD Cowen Genetic Medicines & RNA Summit on Friday, June 21, 2024, at 11:20 am ET.
Neutral
GlobeNewsWire
6 months ago
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Initial Data from Ongoing MyPEAK™ - 1 Phase 1b of TN-201 Expected in Second Half of 2024
Neutral
GlobeNewsWire
7 months ago
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
Abstracts Demonstrate Tenaya's Continued Innovation Across Core Competencies Facilitating Current Pipeline and Enabling Next Wave of Precision Heart Medicines Abstracts Demonstrate Tenaya's Continued Innovation Across Core Competencies Facilitating Current Pipeline and Enabling Next Wave of Precision Heart Medicines
Neutral
GlobeNewsWire
8 months ago
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Initial Data from Ongoing MyPeak™-1 Phase 1b of TN-201 for MYBPC3-associated HCM Expected in Second Half of 2024 On Track to Dose First Patient in RIDGE™-1Phase 1b Clinical Trial of TN-401 for PKP2-associated ARVC in Second Half 2024 $47 Million Net Proceeds from Recent Financing Extends Cash Runway into Second Half of 2025 SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
Neutral
GlobeNewsWire
8 months ago
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
Charts implemented using Lightweight Charts™